α-interferon treatment induces quantitative modifications of HLA class I-associated peptides eluted from cultured cancer cell lines

被引:5
作者
Cangemi, G
Millo, E
Damonte, G
Semino, C
Pietra, G
Benatti, U
Melioli, G
机构
[1] Ctr Biotecnol Avanzate, Unita Immunoterapia Cellulare, Ist Nazl Ric Canc, I-16132 Genoa, Italy
[2] Univ Genoa, DIMES, Sezione Biochim, Genoa, Italy
来源
TISSUE ANTIGENS | 2000年 / 55卷 / 03期
关键词
high-performance liquid chromatography; HLA class I; mass-spectrometry; peptides; alpha-interferon;
D O I
10.1034/j.1399-0039.2000.550304.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Interferons upregulate the expression of HLA class I antigens on cancer cells. Nevertheless, little is known about the panel of HLA class I antigen-associated peptides presented by recombinant alpha-interferon (r alpha-IFN)-treated cells. For this reason, peptides were eluted from five cancer cell lines (four melanoma and one non-small cell lung cancer) following treat ment with m-IFN. High-performance liquid chromatography (HPLC) profiles of the peptide fractions were compared with those obtained from untreated cells. No significant differences in peptide characteristics (detectable on the basis of retention times) were observed, but significant differences in terms of peptide quantities were observed. Mass spectrometry performed on HPLC peaks allowed not only the detection of three different peptides (two derived from the MAGE family of genes and one from the mart-1) both in untreated and in treated cells, but also gave an indication of the number of peptides within one HPLC peak. This data demonstrates that r alpha-IFN-treated cells express a similar peptide pattern as untreated cells, with significant quantitative differences. Interestingly, this finding also explains the higher susceptibility to lysis (mediated by specific cytolytic lymphocytes, which recognize cancer cells in an HLA-restricted fashion) of r alpha-IFN-treated cells.
引用
收藏
页码:212 / 218
页数:7
相关论文
共 24 条
[1]   Altered MHC class I antigens in tumors [J].
Algarra, I ;
Collado, A ;
Garrido, F .
INTERNATIONAL JOURNAL OF CLINICAL & LABORATORY RESEARCH, 1997, 27 (02) :95-102
[2]   MONOCLONAL ANTIBODIES FOR ANALYSIS OF THE HLA SYSTEM [J].
BRODSKY, FM ;
PARHAM, P ;
BARNSTABLE, CJ ;
CRUMPTON, MJ ;
BODMER, WF .
IMMUNOLOGICAL REVIEWS, 1979, 47 :3-61
[3]  
CHANG JY, 1983, METHOD ENZYMOL, V91, P79
[4]  
COHEN EP, 1994, SEMIN CANCER BIOL, V5, P419
[5]   Adherent neoplastic cells grown at confluence downregulate HLA class I expression and enhance their susceptibility to lysis mediated by natural killer cells [J].
Ferlazzo, G ;
Semino, C ;
Quartarone, G ;
Pietra, G ;
Melioli, G .
TISSUE ANTIGENS, 1997, 50 (05) :459-465
[6]   Implications for immunosurveillance of altered HLA class I phenotypes in human tumours [J].
Garrido, F ;
RuizCabello, F ;
Cabrera, T ;
PerezVillar, JJ ;
LopezBotet, M ;
DugganKeen, M ;
Stern, PL .
IMMUNOLOGY TODAY, 1997, 18 (02) :89-95
[7]   HUMAN GENE MAGE-3 CODES FOR AN ANTIGEN RECOGNIZED ON A MELANOMA BY AUTOLOGOUS CYTOLYTIC T-LYMPHOCYTES [J].
GAUGLER, B ;
VANDENEYNDE, B ;
VANDERBRUGGEN, P ;
ROMERO, P ;
GAFORIO, JJ ;
DEPLAEN, E ;
LETHE, B ;
BRASSEUR, F ;
BOON, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (03) :921-930
[8]   INTRAPERITONEAL ADMINISTRATION OF INTERFERON-GAMMA TO CARCINOMA PATIENTS ENHANCES EXPRESSION OF TUMOR-ASSOCIATED GLYCOPROTEIN-72 AND CARCINOEMBRYONIC ANTIGEN ON MALIGNANT ASCITES-CELLS [J].
GREINER, JW ;
GUADAGNI, F ;
GOLDSTEIN, D ;
SMALLEY, RV ;
BORDEN, EC ;
SIMPSON, JF ;
MOLINOLO, A ;
SCHLOM, J .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (05) :735-746
[9]  
IMAI K, 1981, J IMMUNOL, V127, P505
[10]   IDENTIFICATION OF THE IMMUNODOMINANT PEPTIDES OF THE MART-1 HUMAN-MELANOMA ANTIGEN RECOGNIZED BY THE MAJORITY OF HLA-A2-RESTRICTED TUMOR-INFILTRATING LYMPHOCYTES [J].
KAWAKAMI, Y ;
ELIYAHU, S ;
SAKAGUCHI, K ;
ROBBINS, PF ;
RIVOLTINI, L ;
YANNELLI, JR ;
APPELLA, E ;
ROSENBERG, SA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (01) :347-352